Clinical trial · Interventional
Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL
Efficacy and Safety of Targeted Drugs Combined With Chemotherapy in the Treatment of Patients With Newly Diagnosed Acute T-lymphocytic Leukemia
NCT07203352CI-TRIAL-00096135recruitingPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This prospective, randomized, controlled trial evaluates the efficacy and safety of a new targeted drug combined with chemotherapy versus standard chemotherapy alone. Eligible patients were randomized 1:1 to either the treatment or control group.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| targeted drug | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- experimental group
- description
- The subjects randomly assigned to the experimental group received targeted drug treatment in addition to the chemotherapy regimen during the second course. Based on the results of bone marrow PCR, subjects with molecular typing of ABL1/ABL2/PDGFRB fusion were to receive chemotherapy combined with dasatinib 100mg orally once a day; subjects with molecular typing of FLT3-ITD positive were to receive chemotherapy combined with sorafenib 400mg orally twice a day.
- interventionNames
- Drug: targeted drug
- type
- NO_INTERVENTION
- label
- control group
- description
- Patients randomly assigned to the control group will receive standard chemotherapy treatment, but they cannot use targeted drugs in combination.
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. The subjects were diagnosed with acute T-lymphocytic leukemia (according to the 2016 WHO classification) based on their bone marrow pathology and hematology, and sufficient bone marrow samples were available for PCR analysis; 2. The subjects must have never received anti-leukemia treatment before; 3. Age ≥ 18 years old, gender not restricted; 4. The subjects' Eastern Cooperative Oncology Group (ECOG) performance status score is 0-2; 5. The subjects or their legal representatives must provide written informed consent before undergoing the special examinations or procedures of the study. Exclusion Criteria: 1. Classified as other types of leukemia according to the WHO 2016 classification; 2. Previously received systemic or local treatments including chemotherapy; 3. Previously underwent hematopoietic stem cell transplantation; 4. Had other tumors in addition to leukemia; 5. Had uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, severe infectious diseases, etc.; 6. Patients with a history of allergic reactions to any drugs in this research protocol; 7. Left ventricular ejection fraction ≤ 50%; 8. Laboratory test values at screening (unless caused by leukemia): ALT or AST higher than twice the upper limit of normal, AKP and bilirubin higher than 1.5 times the upper limit of normal, creatinine level higher than 1.5 times the upper limit of normal; 9. Other concurrent and uncontrolled medical conditions that the researcher considers will affect the patient's participation in the study; 10. Psychiatric patients or other patients known or suspected to be unable to fully comply with the study protocol; 11. Pregnant or lactating women; 12. HIV-infected individuals.
References
Publications (0)
Data not yet available
No reference posted for this study.